BIOCRYST PHARMACEUTICALS, INC. Net Fee Amt
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Net Fee Amt of $8.79 thousand as of 2026-08-04, per its S-8 filed 2026-08-05.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-05
- 2026-08-04: Net Fee Amt $8.79K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $8.79K S-8 · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |